Comparing Globus Medical (NYSE:GMED) & Adynxx (NYSE:ADYX)

Share on StockTwits

Globus Medical (NYSE:GMED) and Adynxx (OTCMKTS:ADYX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Risk & Volatility

Globus Medical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Adynxx has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Globus Medical and Adynxx, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Globus Medical 0 3 10 0 2.77
Adynxx 0 0 0 0 N/A

Globus Medical presently has a consensus target price of $60.15, indicating a potential upside of 23.04%. Given Globus Medical’s higher possible upside, analysts plainly believe Globus Medical is more favorable than Adynxx.

Institutional and Insider Ownership

66.6% of Globus Medical shares are held by institutional investors. 25.6% of Globus Medical shares are held by insiders. Comparatively, 17.4% of Adynxx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Globus Medical and Adynxx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Globus Medical 11.90% 9.58% 8.79%
Adynxx N/A N/A N/A

Valuation and Earnings

This table compares Globus Medical and Adynxx’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Globus Medical $785.37 million 6.09 $155.21 million $1.68 29.10
Adynxx $2.22 million 0.03 -$8.42 million N/A N/A

Globus Medical has higher revenue and earnings than Adynxx.

Summary

Globus Medical beats Adynxx on 10 of the 11 factors compared between the two stocks.

Globus Medical Company Profile

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.

Adynxx Company Profile

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply